Atai Beckley Inc Stock Price, News & Analysis

Atai Beckley (NASDAQ: ATAI) will participate in the Jefferies Global Healthcare Conference in London.

Who: Srinivas Rao, M.D., Ph.D., CEO, and Kevin Craig, M.D., CMO. Format: Fireside chat and one-on-one investor meetings. When: Fireside chat on Thursday, November 20, 2025 at 11:30 A.M. GMT / 6:30 A.M. ET. Webcast: A live webcast is provided and an archived replay will be available on the company Investors Events page for up to 90 days.

AtaiBeckley (NASDAQ: ATAI) reported Q3 2025 results and corporate updates highlighting clinical and financing milestones. Key items include FDA Breakthrough Therapy designation for BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression, positive Phase 2a and Phase 2b OLE topline data for BPL-003, and an End-of-Phase 2 meeting with FDA with Phase 3 guidance expected in Q1 2026 and anticipated Phase 3 start in Q2 2026. The company completed enrollment in the Phase 2a EMP-01 study for social anxiety disorder and expanded VLS-01 Phase 2 sites internationally. AtaiBeckley closed an approximate $150 million public offering, reported cash, cash equivalents and short-term securities of $114.6 million as of Sept 30, 2025, and expects liquidity to fund operations into 2029. The company also secured a NIDA grant worth up to $11.4 million for novel 5-HT2A/2C programs.

AtaiBeckley (NASDAQ: ATAI) reported positive topline results from the Phase 2b open-label extension (OLE) of BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression on Nov 10, 2025.

Key findings: a 12 mg re-dose eight weeks after an initial dose produced additional rapid antidepressant effects sustained up to eight weeks; pooled active-core patients (n=60) showed a mean MADRS reduction of 19.0 points and 63% responder / 48% remission at Day 57 (Week 16). Safety was consistent with prior studies; most adverse events were mild/moderate and transient; one drug-related serious adverse event resolved.

The company scheduled an End-of-Phase 2 meeting with the FDA and expects Phase 3 guidance in Q1 2026 with potential initiation in Q2 2026.

AtaiBeckley (NASDAQ: ATAI) announced completion of the strategic combination between atai Life Sciences and Beckley Psytech on Nov 5, 2025, creating a clinical‑stage company focused on psychedelic‑based neuroplastogens.

Key facts: BPL-003 is Phase 3‑ready with FDA Breakthrough Therapy designation and Phase 3 initiation expected Q2 2026; VLS-01 topline data expected H2 2026; EMP-01 topline data expected Q1 2026. Management and board roles were established and the company expects cash and liquid assets to fund operations into 2029. The deal issues ~105 million new shares (~28% of combined company) and a Delaware redomiciliation is expected around year‑end.

atai Life Sciences (NASDAQ: ATAI) closed a public offering on October 20, 2025, issuing 27,283,750 common shares (including full exercise of a 3,558,750-share underwriter option) at $5.48 per share.

The offering generated approximately $149.5 million in aggregate gross proceeds before fees. atai said it will use net proceeds together with existing cash and liquid assets to fund its pipeline, including the planned Phase 3 program for BPL-003 through first top-line readout, completion of the Phase 2 VLS-01 trial and the Phase 2a EMP-01 study, plus working capital. Based on this use, atai estimates cash will fund operations into 2029.

atai Life Sciences (NASDAQ: ATAI) priced an underwritten public offering of 23,725,000 common shares at $5.48 per share and granted underwriters a 30-day option to buy up to an additional 3,558,750 shares. Gross proceeds are expected to be approximately $130 million before fees. The company said it will use net proceeds, together with existing cash and short-term investments, to advance clinical development of product candidates and for working capital and general corporate purposes. The offering is expected to close on October 20, 2025, subject to customary closing conditions, with Jefferies as lead bookrunner.

atai Life Sciences (NASDAQ: ATAI) announced on October 16, 2025 the commencement of a proposed registered underwritten offering of its common shares.

The company said it expects to grant underwriters a 30-day option to purchase additional common shares and that all shares will be sold by atai. The offering is subject to market and other conditions and may not be completed.

atai intends to use net proceeds, together with existing cash and short-term investments, to advance clinical development, and for working capital and general corporate purposes. Jefferies is lead bookrunner.

atai Life Sciences (NASDAQ: ATAI) and Beckley Psytech announced that the U.S. FDA has granted Breakthrough Therapy designation to BPL-003 (mebufotenin benzoate) nasal spray for adult patients with treatment-resistant depression (TRD).

Designation follows positive Phase 2b topline results where a single 8 mg or 12 mg dose produced clinically meaningful, statistically significant symptom reductions within 24 hours with effects sustained through an 8-week trial; most patients were ready for discharge by 90 minutes post-dose. The companies state Phase 3 trials are expected to begin in Q2 2026, subject to FDA alignment.

atai Life Sciences (NASDAQ: ATAI) and Beckley Psytech announced positive Phase 2a data for their treatment-resistant depression (TRD) drug BPL-003. The study evaluated a two-dose regimen (8mg followed by 12mg after two weeks) in 13 TRD patients.

Key findings showed rapid and durable efficacy with mean MADRS score reductions of 13.3 points at Day 2 and further improvement to 19.0 points after the second dose. Remission rates increased from 25% after the first dose to 50% at Week 8. The treatment demonstrated strong tolerability with only mild to moderate adverse events.

Following these positive results and pending FDA feedback, the companies plan to initiate Phase 3 clinical trials in H1 2026.